BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lefebvre J, Glezerman IG. Kidney Toxicities Associated With Novel Cancer Therapies. Adv Chronic Kidney Dis 2017;24:233-40. [PMID: 28778363 DOI: 10.1053/j.ackd.2017.05.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Ackerman RS, Muncey AR, Aldawoodi NN, Kotha R, Getting REG. Cancer Immunotherapies: What the Perioperative Physician Needs to Know. Curr Oncol Rep 2022. [PMID: 35141856 DOI: 10.1007/s11912-022-01202-6] [Reference Citation Analysis]
2 Gutierrez C, McEvoy C, Munshi L, Stephens RS, Detsky ME, Nates JL, Pastores SM. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Crit Care Med 2020;48:10-21. [PMID: 31725440 DOI: 10.1097/CCM.0000000000004087] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
3 Sun G, Liu H, Shi X, Tan P, Tang W, Chen X, Sun G, Yang W, Kong X, Zheng Z, Cao H, Shao G. Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review). Int J Oncol 2022;60:74. [PMID: 35485291 DOI: 10.3892/ijo.2022.5364] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zhang H, Ye Q, Du Z, Huang M, Zhang M, Tan H. MiR-148b-3p inhibits renal carcinoma cell growth and pro-angiogenic phenotype of endothelial cell potentially by modulating FGF2. Biomed Pharmacother 2018;107:359-67. [PMID: 30099339 DOI: 10.1016/j.biopha.2018.07.054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
5 Voigtlaender M, Langer F. Management of cancer-associated venous thromboembolism - a case-based practical approach. Vasa 2018;47:77-89. [PMID: 29325495 DOI: 10.1024/0301-1526/a000684] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Awdishu L, Atilano-Roque A, Tuey S, Joy MS. Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using "Omic" Strategies. Pharmgenomics Pers Med 2020;13:687-705. [PMID: 33293850 DOI: 10.2147/PGPM.S239471] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kitchlu A, McArthur E, Amir E, Booth CM, Sutradhar R, Majeed H, Nash DM, Silver SA, Garg AX, Chan CT, Kim SJ, Wald R. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study. J Natl Cancer Inst 2019;111:727-36. [PMID: 30423160 DOI: 10.1093/jnci/djy167] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
8 Scotté F, Leroy P, Chastenet M, Aumont L, Benatar V, Elalamy I. Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. Cancers (Basel) 2019;11:E48. [PMID: 30621020 DOI: 10.3390/cancers11010048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. J Med Toxicol 2021. [PMID: 33826117 DOI: 10.1007/s13181-021-00833-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford) 2019;58:vii7-vii16. [PMID: 31816085 DOI: 10.1093/rheumatology/kez418] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 17.5] [Reference Citation Analysis]